254.87
+2.63%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biogen
From its filings with the US Securities and Exchange Commission
Biogen is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BIIB. It is a member of the S&P 500. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $9.89bn and net income of $1.29bn. At that date it held total assets of $29.44bn and shareholders' equity of $18.26bn.
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer’s disease and launched the first approved treatment to target a genetic cause of ALS. We market the first and only drug approved in the U.S., the E.U. and certain international markets for the treatment of FA in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.
Our marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.
Quoted from its 10-K, filed 6 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Sept 1991
- Employees
- 7,500
- Website
- biogen.com ↗
- Head office
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Caroline DorsaIndependent Chairman of the Board$629,840
- Mr. Christopher ViehbacherPresident, Chief Executive Officer, Director, since 2022$24.2m
- Ms. Robin KramerChief Financial Officer, Executive Vice President
- Dr. Ginger GregoryChief Human Resources Officer, Executive Vice President$5.1m
- Ms. Susan AlexanderExecutive Vice President, Chief Legal Officer$6.5m
- Dr. Jane GroganExecutive Vice President, Head of Research
- Mr. Rachid IzzarExecutive Vice President, Head of Global Product Strategy and Commercialization$5.4m
- Dr. Adam KeeneyExecutive Vice President, Head of Corporate Development
- Ms. Nicole MurphyExecutive Vice President - Pharmaceutical Operations and Technology$5.7m
- Dr. Priya SinghalExecutive Vice President, Head of Development$6.4m
- Mr. Sean GodboutChief Accounting Officer, Vice President, Global Corporate Controller, Principal Accounting Officer
- Dr. Maria FreireIndependent Director$443,771
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 83
- Environment
- 88
- Social
- 81
- Governance
- 80
- Direct emissions (scope 1)
- 56,611 t
- Energy emissions (scope 2)
- 32,858 t
- Value chain emissions (scope 3)
- 267,059 t
- Women in the workforce
- 52.5%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biogen Inc is a prominent biotechnology company with a strong presence in the industry. It has a solid track record of developing innovative drugs and therapies.
- Biogen Inc offers a diversified range of products, including treatments for multiple sclerosis, spinal muscular atrophy, and hemophilia. This diversified portfolio reduces its dependency on a single product and contributes to its overall revenue stability.
- The company invests significantly in research and development, allowing it to stay at the forefront of medical advancements and develop cutting-edge therapies.
Weaknesses
- Biogen Inc heavily relies on a few key products, such as Tecfidera and Spinraza, for a significant portion of its revenue. This creates vulnerability if any of these products face challenges or competition.
- As a biotechnology company, Biogen Inc faces regulatory risks associated with drug approvals and ongoing compliance. Changes in regulatory policies can impact the company's ability to bring new products to market or maintain existing product lines.
Opportunities
- The global biopharmaceutical market is expanding rapidly, providing significant growth opportunities for Biogen Inc. The company can leverage its expertise and expand into new regions to capture a larger market share.
- Biogen Inc can benefit from investing in innovative technologies, such as gene therapies and personalized medicine. These advancements have the potential to revolutionize the healthcare industry and offer new avenues for growth.
Threats
- Biogen Inc operates in a highly competitive industry with several other major pharmaceutical and biotechnology companies. Intense competition can impact pricing, market share, and profitability.
- Protecting intellectual property rights is crucial for Biogen Inc, as competitors may attempt to replicate or challenge its products. Any infringement or loss of intellectual property could negatively impact the company's revenue and market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.